0 min read(BPRW) Vivacelle Bio Announces Early Results of its Phase IIa Clinical Trial of VBI-S for Improving Hypovolemia Due to Sepsis
Selective nitric oxide redistribution by phospholipid nanoparticles: A novel strategy to mitigate massive nitric oxide release and prevent reperfusion injury in septic shock
Vivacelle Bio Commemorates Sepsis Awareness Month, Recognizing the Leading Cause of Death in U.S. Hospitals
.jpg){kind=logo}
Comments